Pathways relevant to Alzheimer's disease are identified during proinflammatory activation from a microglial model derived from human monocytes.

Therefore, our study indicated that a human monocyte-derived microglia model treated with a pro-inflammatory agent such as LPS could provide microglia-specific regulations during M1 activation and further identify disease-relevant genes, biological processes, or pathways. The study implements that the microglial model can be used in clinical studies for new biomarker or drug discovery for many neuroinflammatory disorders, including AD. Further studies with this microglial model in AD patients are warranty to verify our finding.